Cargando…

Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas

The therapeutic effect of doxorubicin (DXR) in the treatment of soft tissue sarcomas (STS) is limited by its toxicity and the development of multidrug resistance (MDR), the latter mainly induced by high expression of efflux pumps (e.g., P-glycoprotein [P-gp]). Therefore, the search for alternative t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villar, Victor Hugo, Vögler, Oliver, Martínez-Serra, Jordi, Ramos, Rafael, Calabuig-Fariñas, Silvia, Gutiérrez, Antonio, Barceló, Francisca, Martín-Broto, Javier, Alemany, Regina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360613/ https://www.ncbi.nlm.nih.gov/pubmed/22662203 http://dx.doi.org/10.1371/journal.pone.0037735

Ejemplares similares

Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma
por: Villar, Victor Hugo, et al.
Publicado: (2016)

Evodiamine Synergizes with Doxorubicin in the Treatment of Chemoresistant Human Breast Cancer without Inhibiting P-Glycoprotein
por: Wang, Shengpeng, et al.
Publicado: (2014)

WNT/β-Catenin Pathway in Soft Tissue Sarcomas: New Therapeutic Opportunities?
por: Martinez-Font, Esther, et al.
Publicado: (2021)

α-bisabolol Is an Effective Proapoptotic Agent against BCR-ABL(+) Cells in Synergism with Imatinib and Nilotinib
por: Bonifacio, Massimiliano, et al.
Publicado: (2012)

Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein.
por: Schuurhuis, G. J., et al.
Publicado: (1991)

Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade
por: Ocadlikova, Darina, et al.
Publicado: (2021)

Nilotinib Enhances Tumor Angiogenesis and Counteracts VEGFR2 Blockade in an Orthotopic Breast Cancer Xenograft Model with Desmoplastic Response
por: Zafarnia, Sara, et al.
Publicado: (2017)

Nanotechnological approaches for counteracting multidrug resistance in cancer
por: Martinelli, Chiara, et al.
Publicado: (2020)

Doxorubicin metabolism moderately attributes to putative toxicity in prodigiosin/doxorubicin synergism in vitro cells
por: Lin, Shian-Ren, et al.
Publicado: (2020)

Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study
por: Fernandez-Serra, Antonio, et al.
Publicado: (2020)

Impact of Wnt/β-Catenin Inhibition on Cell Proliferation through CDC25A Downregulation in Soft Tissue Sarcomas
por: Martinez-Font, Esther, et al.
Publicado: (2020)

Nilotinib-Associated Destructive Thyroiditis
por: Bakerywala, Suhalia, et al.
Publicado: (2015)

Nilotinib-Induced Keratosis Pilaris
por: Leong, Wai Mun Sean, et al.
Publicado: (2016)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)
por: Shen, Tong, et al.
Publicado: (2009)

Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity
por: Jiang, Jiangsong, et al.
Publicado: (2017)

Correction: Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)
por: Shen, Tong, et al.
Publicado: (2009)

Nilotinib based pharmacophore models for BCRABL
por: Sabitha, Kesavan
Publicado: (2012)

Nilotinib – Differentiating the Hope from the Hype
por: Wyse, Richard K., et al.
Publicado: (2016)

Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna(®)) with the human ABC drug transporter P-glycoprotein
por: Shukla, Suneet, et al.
Publicado: (2014)

Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma
por: Brand, Caroline, et al.
Publicado: (2020)

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
por: Hochhaus, Andreas, et al.
Publicado: (2015)

Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy
por: Zhang, Chun-ge, et al.
Publicado: (2016)

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells
por: Pichot, C S, et al.
Publicado: (2009)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Immunotherapy Plus Radiotherapy for the Treatment of Sarcomas: Is There a Potential for Synergism?
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Calli Essential Oils Synergize with Lawsone against Multidrug Resistant Pathogens
por: Soliman, Sameh S. M., et al.
Publicado: (2017)

The human amniotic fluid stem cell secretome effectively counteracts doxorubicin-induced cardiotoxicity
por: Lazzarini, Edoardo, et al.
Publicado: (2016)

Effects of nilotinib on regulatory T cells: the dose matters
por: Fei, Fei, et al.
Publicado: (2010)

Nilotinib-induced Perforating Folliculitis: Two Cases
por: Saraswat, Neerja, et al.
Publicado: (2018)

Nilotinib: QTc prolongation: 2 case reports
Publicado: (2021)

Interaction of tamoxifen with the multidrug resistance P-glycoprotein.
por: Callaghan, R., et al.
Publicado: (1995)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Enhanced antitumor efficacy of doxorubicin-encapsulated halloysite nanotubes
por: Li, Kai, et al.
Publicado: (2017)

Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance
por: Martirosyan, Anna, et al.
Publicado: (2010)

Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
por: Veltman, Joris D., et al.
Publicado: (2010)

Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models
por: Rios-Doria, Jonathan, et al.
Publicado: (2015)

Short-Term Fasting Synergizes with Solid Cancer Therapy by Boosting Antitumor Immunity
por: de Gruil, Nadia, et al.
Publicado: (2022)

Thrombospondin-1 Receptor CD47 Overexpression Contributes to P-Glycoprotein-Mediated Multidrug Resistance Against Doxorubicin in Thyroid Carcinoma FTC-133 Cells
por: Courageot, Marie-Pierre, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jooh71i8o9kkkhel9n90qcb23t